Written and maintained by CASRAI Editorial Board
Last updated
The Digital Medicine Society (DiMe) is a global 501(c)(3) non-profit scientific society founded in 2019 to advance the ethical, effective, equitable, and safe use of digital medicine to redefine healthcare and clinical research. Serving as a cross-disciplinary collaboration hub for biomedical engineers, clinical trialists, biostatisticians, clinicians, pharmaceutical sponsors, and regulatory scientists, DiMe develops open-source evidentiary frameworks—most notably the V3 validation framework (Verification, Analytical Validation, and Clinical Validation) for Biometric Monitoring Technologies (BioMeTs) and the crowdsourced Library of Digital Endpoints.
What Is the Digital Medicine Society (DiMe) and How Is It Used in Clinical Research and Healthcare?
In clinical research and healthcare delivery, digital health technologies (DHTs)—such as medical-grade wearables, actigraphy sensors, continuous glucose monitors, ambient physiological monitors, and smartphone-based assessments—generate high-frequency longitudinal data outside traditional clinic walls. Before DiMe was established, terminology and validation standards fragmented across engineering, clinical medicine, and regulatory affairs: hardware engineers used “validation” to describe benchtop signal accuracy, whereas clinical trialists used the same term to describe clinical endpoint correlation.
DiMe bridges these disciplines by producing peer-reviewed consensus standards, open-source toolkits, and multi-stakeholder playbooks that standardize how digital clinical measures are developed and deployed:
- The Playbook (Digital Clinical Measures Playbook): Co-developed by pharmaceutical sponsors, technology vendors, and patient advocates, The Playbook establishes a step-by-step operational blueprint for selecting meaningful aspects of health (MAH), defining concepts of interest (COI), selecting fit-for-purpose sensor hardware, and executing decentralized or hybrid clinical trials.
- DATAcc by DiMe (Digital Health Measurement Collaborative Community): Operating as an FDA-participating Collaborative Community aligned with the FDA Digital Health Center of Excellence (DHCoE), DATAcc convenes regulators, payers, and researchers to establish standardized core sets of digital clinical measures (such as nocturnal scratch in atopic dermatitis, physical activity in heart failure, and sleep disturbance) and health-economic value frameworks.
- Library of Digital Endpoints: An open-access, continuously curated registry documenting industry-sponsored trials that utilize digital biomarkers and sensor-derived endpoints as primary, secondary, or exploratory outcomes to support medical product labeling or coverage decisions.
The DiMe V3 Framework: Verification, Analytical Validation, and Clinical Validation
Published by Goldsack et al. (2020) in npj Digital Medicine (3:55), the V3 Framework is DiMe’s foundational methodology for determining whether a Biometric Monitoring Technology (BioMeT)—defined as a connected digital medicine product that processes mobile sensor data using algorithms to generate measures of behavioral or physiological function—is fit-for-purpose for a specific clinical trial or care pathway.
| V3 Stage | Primary Question Answered | Study Setting & Subjects | Reference Standard / Ground Truth | Primary Responsibility & Output |
|---|---|---|---|---|
| 1. Verification | Does the sensor hardware and firmware accurately measure the raw physical signal it claims to capture? | Benchtop laboratory testing (no human participants required). | Calibrated physical reference instruments (e.g., orbital shaker table for accelerometers in $g$, optical phantom for PPG sensors). | Hardware/firmware engineers; yields sample-level signal accuracy, precision, noise floor, and inter-sensor reliability metrics. |
| 2. Analytical Validation | Does the algorithm processing the verified sensor output accurately measure the physiological or behavioral metric in humans? | Controlled human laboratory or structured free-living study in healthy volunteers and/or target patients. | Established physiological or clinical reference instrument (e.g., 12-lead ECG for heart rate/HRV, in-lab polysomnography for sleep stages, video-annotated gait mat for stride velocity). | Data scientists and clinical investigators; yields epoch-by-epoch sensitivity, specificity, Bland-Altman limits of agreement, and Intraclass Correlation Coefficients (ICC). |
| 3. Clinical Validation | Does the analytically validated digital measure meaningfully reflect how the target patient population feels, functions, or survives? | Prospective clinical trials or observational cohorts in the specific target disease population and context of use (COU). | Validated clinical outcomes, survival, disease severity scales, or Patient-Reported Outcome Measures (PROMs). | Clinical trialists, biostatisticians, and medical sponsors; establishes construct validity, known-groups discrimination, responsiveness to change, and Minimal Clinically Important Difference (MCID). |
Crucially, V3 is not a one-time product certification. While Verification is tied to the physical sensor hardware and firmware version, Analytical Validation must be re-evaluated if the population’s movement or physiology alters signal morphology (for example, validating a step-counting algorithm in Parkinsonian shuffling gait or unilateral hemiparesis rather than healthy young adults), and Clinical Validation is strictly specific to the target disease indication and regulatory Context of Use (COU).
What Standards or Regulatory Requirements Govern Digital Medicine Society Frameworks?
Although DiMe is a non-profit scientific society rather than a statutory regulator, its V3 framework and endpoint standards directly align with binding and guidance-level regulatory requirements issued by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA):
- FDA Final Guidance on Digital Health Technologies for Remote Data Acquisition in Clinical Investigations (December 2023): The FDA explicitly adopts the verification and validation paradigm when sponsors submit Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications incorporating DHTs. Sponsors must document hardware verification, algorithmic validation across diverse demographic and skin-tone subgroups (for optical photoplethysmography and pulse oximetry sensors), human factors usability evaluations, and cybersecurity controls.
- FDA Biomarker and COA Qualification Programs (DDT): Digital measures developed using DiMe’s concept-to-outcome hierarchy (Meaningful Aspect of Health → Concept of Interest → Digital Clinical Measure) map onto the FDA’s Drug Development Tool (DDT) qualification pathway for Digital Health Technologies and Digital Therapeutics (DTx).
- EMA Qualification of Novel Methodologies for Medicine Development: The EMA’s breakthrough qualification of Stride Velocity 95th Centile (SV95C)—measured via a wearable ankle-worn magneto-inertial sensor in Duchenne Muscular Dystrophy (DMD)—as a primary endpoint followed the exact evidentiary hierarchy of hardware verification, analytical validation against motion-capture laboratories, and longitudinal clinical validation against the 6-Minute Walk Test (6MWT) and North Star Ambulatory Assessment (NSAA).
- 21 CFR Part 11 and ALCOA+ Data Integrity: Sensor data streams and derived digital endpoints used in regulated clinical investigations must maintain Attributable, Legible, Contemporaneous, Original, and Accurate (ALCOA+) provenance, time-synchronized UTC timestamps, firmware/algorithm version locking, and immutable audit trails from raw sensor packet capture through statistical analysis datasets (CDISC SDTM/ADaM).
How Does Digital Medicine Society Architecture Integrate with EHR and Health Informatics Workflows?
Translating digital clinical measures from research-grade BioMeTs into decentralized clinical trials (DCTs)—managed on platforms such as Medable—and routine electronic health record (EHR) care pathways requires standardized health informatics pipelines:
- Raw-to-Epoch Sensor Ingestion Architecture: Wearable and ambient BioMeTs transmit raw waveform data (such as 32–100 Hz tri-axial accelerometer streams or 125–250 Hz single-lead ECG) via Bluetooth Low Energy (BLE) to a mobile gateway app or cellular hub, which uploads encrypted packets to a cloud ingestion pipeline. Versioning metadata (`Device` firmware ID and algorithm container hash) is attached to every derived epoch to prevent silent algorithmic drift mid-trial.
- HL7 FHIR R4 Resource Mapping: When digital measures are integrated into clinical EHR workflows or FHIR-enabled clinical data repositories, sensor hardware metadata is represented using the
DeviceandDeviceMetricresources, while derived physiological and behavioral summaries (such as daily mean step count, resting heart rate, nocturnal respiratory rate, or SV95C) map toObservationresources coded with standardized LOINC and IEEE 11073 nomenclature codes. - CDISC SDTM Representation for Regulatory Submissions: In pharmaceutical trials, derived digital endpoints are mapped into CDISC Study Data Tabulation Model (SDTM) domains—such as Vital Signs (
VS), Nervous System Findings (NV), Musculoskeletal System Findings (MK), or Functional Tests (FT)—linked via the Device Identifiers (DI) and Device-In-Use (DU) domains to preserve full traceability between the participant, the physical sensor serial number, and the analytical algorithm version.
Frequently Asked Questions
What is the Digital Medicine Society (DiMe) and how is it used in clinical research and healthcare?
The Digital Medicine Society (DiMe) is a 501(c)(3) non-profit professional organization founded in 2019 that develops consensus scientific standards for digital health technologies. In clinical research and healthcare, investigators and sponsors use DiMe’s V3 validation framework, The Playbook, and the open-source Library of Digital Endpoints to select, validate, and deploy wearable sensors and digital biomarkers as fit-for-purpose clinical trial endpoints and remote monitoring tools.
What standards or regulatory requirements govern Digital Medicine Society frameworks?
DiMe’s V3 framework (Verification, Analytical Validation, and Clinical Validation) aligns directly with the FDA’s December 2023 final guidance on Digital Health Technologies for Remote Data Acquisition in Clinical Investigations, FDA Drug Development Tool (DDT) qualification programs, EMA novel methodology qualification guidelines, and 21 CFR Part 11 / ICH E6(R3) electronic source data integrity requirements.
How does Digital Medicine Society guidance integrate with EHR and health informatics workflows?
DiMe-aligned digital clinical measures integrate with EHRs and trial databases by pairing every derived physiological or behavioral metric with its hardware firmware and algorithm version metadata. In health informatics systems, sensor provenance maps to HL7 FHIR R4 Device and DeviceMetric resources, derived measures map to LOINC-coded FHIR Observation resources, and regulatory trial datasets map to CDISC SDTM findings domains linked to the Device Identifiers (DI) domain.
